Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions.
Want to speed up early discovery of PROTACs and RIPTACs? These heterobifunctional molecules move beyond classical occupancy-driven inhibition to event-driven modulation of protein function, enabling therapeutic targeting of proteins that were previously considered undruggable. This webinar demonstrates how chemical synthesis and in vitro profiling can be combined to rapidly generate, optimize, and advance these molecules in early discovery programs.
Amsbio has expanded its range of iPSC Differentiation Kits that provide fast and flexible generation of specific cell types without sacrificing cell purity.
Applications are invited for a Policy and Public Affairs Manager to join the Communications team at the Quadram Institute, based in Norwich, UK.
Background:
The Policy and Public Affairs Manager will have a critical role in ensuring the impact of the Institute’s work on food, nutrition and human health, is effectively represented to policymakers, funders, government departments, and our external partners.
The role:
Human Biological Samples (HBS) sit at the heart of clinical research, enabling the discovery, development and delivery of new treatments and diagnostics. As ethically sensitive materials, they underpin every clinical trial and demand rigorous handling and oversight. The Senior Biobank Scientist maintains and develops the HBS inventory in line with Good Clinical Practice (GCP), global standards and standard operating procedures (SOPs), ensuring samples are received, logged, stored, tracked, despatched, returned and disposed of appropriately.
About the Team
In service of its world-leading life sciences services, training, and research, the Applications team within ITS operates a substantial platform based on circa 120 Kubernetes clusters, combining a large VMware on-premises estate with a growing presence in public cloud.
We are now building upon this success and have launched a new, significant fundraising campaign. This campaign will help drive further transformational growth, from income across major donors, trusts and foundations, and corporate partners. Ultimately, it will help us fund cutting-edge research that will bring forward the day when we can diagnose, treat and prevent dementia.
Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ partnered with AstraZeneca). Astex continues to grow and focuses on Neurological Disorders and Oncology.
The Role
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.